Dividend Power Score
A single, comprehensive score designed to measure the true strength of a company’s dividend.
This score combines three essential pillars of dividend quality:
Consistency – Measures how reliable the dividend has been over time, focusing on payment history, stability, and the absence of cuts or suspensions.
Payability – Assesses the company’s financial ability to sustain its dividend, taking into account cash flow, earnings coverage, balance sheet strength, and overall financial health.
Growth – Evaluates the long-term growth of both the dividend and the company’s share price, highlighting businesses that consistently increase payouts while creating shareholder value.
Higher scores identify companies that have historically delivered dependable income alongside sustained dividend growth and long-term capital appreciation.
Company Overview
Monopar Therapeutics Inc. is a clinical-stage biotechnology company focused on the development of targeted oncology therapies for patients with serious and rare cancers. The company operates within the biopharmaceutical and oncology drug development industry and concentrates on advancing proprietary therapeutics designed to address significant unmet medical needs where existing treatment options are limited or ineffective. Monopar does not currently market approved products; its activities are centered on research, clinical development, and regulatory advancement.
The company’s primary value drivers are its oncology-focused clinical and preclinical programs, which include antibody-based and targeted therapeutic approaches. Monopar’s strategy emphasizes programs with clear biological rationale, potential for expedited regulatory pathways, and applicability to orphan or narrowly defined cancer populations. Founded in 2014, Monopar Therapeutics has evolved from an early-stage research company into a publicly traded entity listed on Nasdaq under the ticker MNPR, using capital markets to fund its clinical pipeline expansion.
Business Operations
Monopar’s operations are organized around the discovery, development, and clinical evaluation of oncology drug candidates. The company generates no commercial revenue and instead relies on equity financing and strategic collaborations to support its R&D activities. Its pipeline includes MNPR-101, a targeted antibody-based program under clinical evaluation, as well as additional preclinical and earlier-stage oncology assets. The precise clinical scope and comparative differentiation of some programs remain subject to ongoing trials and regulatory review.
Operationally, Monopar maintains a lean organizational structure, outsourcing significant portions of clinical trial execution, manufacturing, and regulatory services to third-party contract research and manufacturing organizations. The company has engaged in strategic collaborations, including partnerships supporting development and manufacturing capabilities for its lead assets. Data inconclusive based on available public sources regarding the full commercial terms or long-term revenue implications of these arrangements.
Strategic Position & Investments
Monopar’s strategic direction is centered on advancing its lead clinical programs through defined development milestones while selectively expanding its pipeline through internal research and external opportunities. Growth initiatives primarily involve progressing existing oncology candidates into later-stage clinical trials and seeking regulatory designations that may accelerate development timelines, such as orphan drug status where applicable.
The company has made targeted investments in its proprietary pipeline rather than broad-based acquisitions. Its portfolio strategy prioritizes capital efficiency and focused execution, with management emphasizing assets that can demonstrate clinical proof-of-concept in relatively small, well-defined patient populations. Data inconclusive based on available public sources regarding any pending acquisitions or late-stage licensing transactions beyond those already disclosed in public filings.
Geographic Footprint
Monopar Therapeutics is headquartered in the United States, with its principal executive offices located in Illinois. The company’s core operations, leadership, and strategic decision-making are U.S.-based, reflecting its focus on the North American biotechnology and capital markets ecosystem.
While Monopar does not maintain extensive physical international operations, its clinical development activities have a global reach through multinational clinical trial sites and international vendors. This approach allows the company to access diverse patient populations and specialized capabilities without establishing permanent overseas facilities.
Leadership & Governance
Monopar is led by an experienced management team with backgrounds in oncology drug development, biotechnology finance, and public company governance. The leadership philosophy emphasizes disciplined capital allocation, scientific rigor, and a targeted approach to oncology innovation aligned with shareholder interests.
Key executives include:
- Chandler D. Robinson – President and Chief Executive Officer
- Andrew C. Keyt – Chief Financial Officer
Information regarding additional executive officers or recent leadership changes is limited; data inconclusive based on available public sources. The company operates under a board-governed structure consistent with U.S. public biotechnology companies and adheres to Nasdaq and SEC governance and disclosure requirements.